Drug intelligence / Profile preview

TML-NEP-19

Development stage: Preclinical
Lead developer: Themis Medicare
Modality: Small Molecules

Overview

TML-NEP-19 is a preclinical-stage analgesic candidate developed by Themis Medicare. It is classified as an opioid and is being developed as a new dosage form, likely utilizing a novel formulation or delivery technology to improve the pharmacokinetic or safety profile of an opioid molecule. The drug is currently in the preclinical phase of development for pain management.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on TML-NEP-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TML-NEP-19.

Explore the full profile